Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Ilford, United Kingdom Clinical Trials

A listing of Ilford, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (61) clinical trials

Gene Therapy for Patients With ADA Adenosine Deaminase (ADA) Deficiency

This is a prospective, non-randomized, single-cohort, longitudinal, single-center, clinical study designed to assess the efficacy and safety of a cryopreserved formulation of OTL-101 (autologous CD34+ hematopoietic stem cells transduced ex vivo with EFS LV encoding for the human ADA gene) administered to ADA-SCID patients between the ages of 30 days ...

Phase

8.76 miles

Learn More »

Durvalumab and Tremelimumab for Pediatric Malignancies

This is a first time in pediatrics study primarily designed to evaluate the safety and tolerability of durvalumab and durvalumab in combination with tremelimumab at increasing doses in pediatric patients with advanced solid malignancies and hematological malignancies (including lymphomas) and for whom no standard of care treatments exist. Although treatment ...

Phase

8.76 miles

Learn More »

Trial of Afatinib in Pediatric Tumours

Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort/Phase II part. The trial will consist of 2 parts: Dose finding part to determine the MTD Biomarker specific MTD expansion cohort/Phase II part to assess clinical anti-tumour activity in included tumour types

Phase

8.81 miles

Learn More »

Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients

The planned study has been designed as a Phase I/II, double-blind, randomised, multi-centre, parallel group study based on information and data available from the administration of Trappsol Cyclo via compassionate/named patient use in patients with NPC-1, and data on other cyclodextrin products in the scientific literature. The study is comprised ...

Phase

8.85 miles

Learn More »

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency

This is a Phase 1/2, open-label, single arm, multicenter, safety and dose finding study of DTX301 in adults with late-onset OTC deficiency. The primary objective of the study is to establish a dose of DTX301 that has a clinically meaningful increase in the rate of ureagenesis. Eligible subjects will receive ...

Phase

8.85 miles

Learn More »

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral Idiopathic Parkinson's Disease

This study consists of two parts. Part A is an open-label dose-escalation phase in which patients are enrolled in cohorts and will receive one of approximately three escalating doses of OXB-102 (AXO-Lenti-PD). Part B is a randomized, double-blind phase in which patients will be randomized to either an active group ...

Phase

8.85 miles

Learn More »

A Study to Determine Dose and Tolerability of CC-220 Monotherapy in Combination With Dexamethasone and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has ...

Phase

9.28 miles

Learn More »

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.

Phase

9.28 miles

Learn More »

Factor VIII Gene Therapy Study in Patients With Hemophilia A

The purpose of this study is to determine the safety and tolerability of the factor VIII gene transfer treatment with BAY 2599023 (DTX201) in individuals with severe hemophilia A.

Phase

9.33 miles

Learn More »

Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy

External beam radiotherapy (EBRT) fails to eradicate prostate cancer in 24-33% of cases. Response is monitored solely by testing serum prostate specific antigen (PSA), with biochemical failure following radiotherapy defined as a prostate specific antigen (PSA) level of 2 ng/ml above the nadir. T2 and Dynamic Contrast Enhanced (DCE) MRI ...

Phase

9.4 miles

Learn More »